Emerging and High Growth Companies

KalGene Pharmaceuticals Inc. in its Series A Financing round (second tranche) of $1.67 million

KalGene Pharmaceuticals Inc.

Home About Us Representative Work

Expertise
Emerging and High Growth Companies
Key Contact
Nathalie Beauregard

Partner, Emerging and High Growth Companies, Montréal

 

On March 29, 2018, KalGene Pharmaceuticals Inc. announced that it had completed its second tranche of Series A financing, raising $1.67 million. The round was led by Merck Lumira Biosciences Fund, L.P. and Merck Lumira Biosciences Fund (Québec), L.P.  

KalGene Pharmaceuticals is a Canadian biotechnology company. It plans to use the funding to support the development of its leading therapeutic medicine for the treatment of Alzheimer’s disease.

Osler, Hoskin & Harcourt LLP represented KalGene Pharmaceuticals with a team consisting of Nathalie Beauregard and Tim Apedaile (Corporate).

Value
$1.67 million
Date Closed
March 29, 2018
Lead Office
Montreal
Key Contact
Nathalie Beauregard

Partner, Emerging and High Growth Companies, Montréal

RELATED EXPERTISE

Find out how we can help you achieve extraordinary results

We have an undisputed reputation for solving problems, removing obstacles, and providing the answers you need, when you need them.

Work with us

Osler is a leading business law firm practising internationally from offices across Canada and in New York. Our clients include industry and business leaders in all segments of the market and at various stages in the growth of their businesses. We have built our reputation on our commitment to our clients' success and the experience, expertise and collaborative approach for which we are recognized. We believe that our success is a reflection of our clients' success.